MHRA approves Spikevax JN.1 COVID-19 vaccines for adults and children from infancy
The MHRA has today, 3 September 2024, approved an adapted Moderna COVID-19 vaccine (Spikevax) that targets the JN.1 COVID-19 subvariant.
The MHRA has today, 3 September 2024, approved an adapted Moderna COVID-19 vaccine (Spikevax) that targets the JN.1 COVID-19 subvariant.